A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) have found a way to switch it back on. In a study published in Science Translational ...
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers and is characterized by the rapid growth of immature myeloid precursor cells. It predominantly affects elderly people, and ...
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the ...
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).
Even when patients with acute myeloid leukemia (AML) appear to be in remission, small numbers of cancer cells can remain in the body. These lingering cells—known as measurable residual disease ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results